Groowe / Newsroom / PVLA

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

PVLA News

Palvella Therapeutics, Inc. Common Stock

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

globenewswire.com Oct 13, 2025 2:00 AM